Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The efficacy of pentosan polysulfate sodium, hydrodistension and combination therapy in patients with bladder pain syndrome.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| pentosan polysulfate cohort | pentosan polysulfate monotherapy | ||
| hydrodistension(HD) cohort | hydrodistension(HD) monotherapy | ||
| combination cohort | combination therapy of pentosan polysulfate and hydrodistension. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| the change of IC-Q symptom index(ICSI)score from baseline to 6 months after each treatment | 6months |
| Measure | Description | Time Frame |
|---|---|---|
| The change of voiding dairy parameters(mean number of micturition,Urgency etc) after each treatment. | 1,2,4 and 6months after each treatment . | |
| The change of O'Leary-Sant Intersttial Cystitis questionnaire (IC-Q)score after each treatment | 1,2,4 and 6months after each treatment . |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Bladder pain syndrome patients have not been treated with hydrodistention.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kyu-Sung Lee, MD,Ph.D | Samsung Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Samsung Medical Center | Seoul | 135-710 | South Korea |
Not provided
| ID | Term |
|---|---|
| D018856 | Cystitis, Interstitial |
| ID | Term |
|---|---|
| D003556 | Cystitis |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| The change of Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) | 1,2,4 and 6months after each treatment . |
| The change of Global Response Assessment(GRA) score | 1,2,4 and 6months after each treatment . |
| The change of EQ-5D Health Questionnaire score | 1,2,4 and 6months after each treatment . |
| The change of Brief Pain Inventory-short form(BPI-sf) score | 1 and 6months after each treatment. |
| The estimation of safty and Complications for each treatment | 1,2,4 and 6months after each treatment . |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |